Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Brain natriuretic peptide increased? 96 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 96 reports of Brain natriuretic peptide increased have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.1% of all adverse event reports for EVOLOCUMAB.

96
Reports of Brain natriuretic peptide increased with EVOLOCUMAB
0.1%
of all EVOLOCUMAB reports
0
Deaths
1
Hospitalizations

How Dangerous Is Brain natriuretic peptide increased From EVOLOCUMAB?

Of the 96 reports, 1 (1.0%) required hospitalization.

Is Brain natriuretic peptide increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 96 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Brain natriuretic peptide increased?

SACUBITRIL\VALSARTAN (252) MACITENTAN (192) TADALAFIL (176) ASPIRIN (157) SELEXIPAG (156) RIVAROXABAN (134) ROSUVASTATIN (133) TAMSULOSIN (131) CLOPIDOGREL BISULFATE (127) TREPROSTINIL (124)

Which EVOLOCUMAB Alternatives Have Lower Brain natriuretic peptide increased Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Brain natriuretic peptide increased Reports All Drugs Causing Brain natriuretic peptide increased EVOLOCUMAB Demographics